Related Experiment Video

Updated: Oct 15, 2025

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.5K

Elevated serum FGF21 predicts the major adverse cardiovascular events in STEMI patients after emergency percutaneous

Lingyun Gu1, Wenlong Jiang1, Huidong Qian1

  • 1Department of Cardiology, Jiangyin Hospital Affiliated to Southeast University, Jiangyin, Jiangsu, China.

Peerj
|October 27, 2021
PubMed

Insights

Elevated serum fibroblast growth factor 21 (FGF21) levels predict major adverse cardiovascular events (MACEs) in ST-segment elevation myocardial infarction (STEMI) patients post-percutaneous coronary intervention (PCI). Higher FGF21 indicates increased MACE risk.

Area of Science:

  • Cardiology
  • Biomarkers
  • Interventional Cardiology

Background:

  • Serum fibroblast growth factor 21 (FGF21) in acute myocardial infarction (AMI) is studied, but its role in ST-segment elevation myocardial infarction (STEMI) post-emergency percutaneous coronary intervention (PCI) remains unclear.
  • Investigating FGF21 as a prognostic biomarker in STEMI patients undergoing emergency PCI is crucial for risk stratification.

Purpose of the Study:

  • To evaluate the predictive value of serum FGF21 levels for major adverse cardiovascular events (MACEs) in STEMI patients after emergency PCI.
  • To compare FGF21 levels between STEMI patients and stable angina (SA) patients.

Main Methods:

  • A cohort of 348 STEMI patients undergoing emergency PCI and 80 SA patients undergoing selective PCI were enrolled.
  • Serum FGF21 levels were measured using ELISA, with a median follow-up of 24 months for MACE assessment.
  • Statistical analyses included linear regression, ROC analysis, Kaplan-Meier curves, and Cox regression.

Main Results:

  • STEMI patients exhibited significantly higher serum FGF21 levels compared to SA patients (P < 0.001).
  • Serum FGF21 levels positively correlated with NT-proBNP (P < 0.001).
  • Higher FGF21 levels were associated with an increased risk of MACEs (HR: 2.011), identifying it as a powerful predictor.

Conclusions:

  • Elevated serum FGF21 levels upon admission are a significant predictor of MACEs in STEMI patients following emergency PCI.
  • FGF21 serves as a valuable prognostic biomarker for risk stratification in this patient population.
Abstract

Keywords:
Fibroblast growth factor 21Major adverse cardiovascular eventsST-segment elevation myocardial infarction

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.5K
Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery08:43

Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery

Published on: February 14, 2017

11.1K

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
44
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
261
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
399